85 results
8-K
EX-99.1
ENTA
Enanta Pharmaceuticals Inc
6 May 24
Results of Operations and Financial Condition
4:05pm
-controlled, human challenge study will evaluate the safety, pharmacokinetics, and changes in viral load measurements and symptoms in up to 114 healthy
8-K
EX-99.1
ENTA
Enanta Pharmaceuticals Inc
7 Feb 24
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024
4:05pm
challenge study in the third quarter of 2024. In this randomized, double-blind, placebo-controlled, human challenge study the safety … -323 is supported by Phase 1 data which demonstrated favorable safety, tolerability, and PK indicative of once-daily dosing, with high exposure
8-K
EX-99.1
ENTA
Enanta Pharmaceuticals Inc
20 Nov 23
Results of Operations and Financial Condition
4:05pm
this is the first time the drug is being dosed in pediatrics, the objective of the first part of the study is to evaluate the safety and pharmacokinetics of EDP-938 … , and safety of EDP-938.
oRSVTx, a Phase 2b, randomized, double-blind, placebo-controlled study in adult hematopoietic cell transplant recipients with RSV
8-K
EX-99.1
e09713f4z0bnvc0wn7n
7 Aug 23
Results of Operations and Financial Condition
4:06pm
8-K
EX-99.1
j2ykr0pv
7 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
3vnwbow
8 May 23
Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million
4:06pm
8-K
EX-99.1
wyf4vv
21 Nov 22
Results of Operations and Financial Condition
4:08pm
8-K
EX-1.1
jvrvuok col
26 Aug 22
Entry into a Material Definitive Agreement
4:10pm
424B5
uhg2jl3b1 96c3gdq9iq
26 Aug 22
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
hw52l9s
8 Aug 22
Results of Operations and Financial Condition
4:04pm
8-K
EX-10.2
qyml2 8bb05zbwok7p2
17 May 22
Entry into a Material Definitive Agreement
4:37pm
8-K
EX-10.3
tiruz5szjo2veh49rjyp
17 May 22
Entry into a Material Definitive Agreement
4:37pm
8-K
EX-99.1
y0x12 mlxo3f7lc
9 May 22
Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter
4:00pm